ремитирующий рассеянный склероз, препараты, изменяющие течение рассеянного склероза, финголимод, суточное мониторирование экг, remitting multiple sclerosis, multiple sclerosis disease modifying drugs, fingolimod, holter ecg monitoring, Medicine

13 patients from the Moscow Multiple Sclerosis Center with remitting MS and not responsive to treatment with 1st line DMD were given Fingolimod (Gilenya) starting from January 2012. After one year of therapy, the group demonstrated a significant decrease in the frequency of exacerbations from 2,54 ± 0,97 to 0,15 ± 0,38 (p ≤ 0,0001) per year, and showed no disability progression according to EDSS. Other results were good tolerability and safety of therapy, no clinically relevant deviations in hematological state, no ophthalmic complications. In view of the possible risk of transient bradycardia, before starting fingolimid therapy MS patients were examined, and their heart was monitored for 6 hours after they were given first dose. The monitoring registered a decrease in heart rate within permissible range (not requiring medical intervention) in 30.76% of cases at 34th hour, and by 6th hour the heart rate returned to the baseline value.